Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Bial","sponsor":"Recipharm AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BIAL and Recipharm Expand Long-Term Supply Agreement for Opicapone API","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"PORTUGAL","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Bial","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BIAL Takes the Lead in Europe for the Commercialisation of Epilepsy Treatment, Zebinix\u00ae Expanding Neurology Footprint","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"PORTUGAL","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Bial","sponsor":"Sunovion Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sunovion and BIAL Enter European Licensing Agreement for Apomorphine Sublingual Film for the Treatment of Parkinson\u2019s Disease OFF Episodes","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"PORTUGAL","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Bial","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BIAL R&D Announces First Patient Dosed in its Phase 2 Clinical Trial of BIA 28-6156 to Treat Parkinson's Disease Patients With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"PORTUGAL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Bial","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS\u00ae (opicapone)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"PORTUGAL","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Bial

    Menu

    Bial

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Bial

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Portugal
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

              Details:

              Under the agreement, Amneal will have exclusive rights to market and distribute ONGENTYS (opicapone), a highly-selective COMT inhibitor, which is approved by USFDA as an add-on treatment to carbidopa/levodopa in patients with Parkinson’s disease experiencing Off episodes.

              Lead Product(s): Opicapone

              Therapeutic Area: Neurology Product Name: Ongentys

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Amneal Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement December 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bial

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Portugal
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BIAL R&D Announces First Patient Dosed in its Phase 2 Clinical Trial of BIA 28-6156 to Treat Parkinson's Disease Patients With a Pathogenic Variant in the Glucocerebrosidas...

              Details:

              BIA 28-6156 is an allosteric activator of the enzyme beta-glucocerebrosidase (GCase) for the treatment of patients with Parkinson's disease (PD) who have a mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).

              Lead Product(s): BIA 28-6156

              Therapeutic Area: Neurology Product Name: BIA 28-6156

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 25, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bial

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Portugal
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sunovion and BIAL Enter European Licensing Agreement for Apomorphine Sublingual Film for the Treatment of Parkinson’s Disease OFF Episodes

              Details:

              Under the terms of the agreement, BIAL will be responsible for regulatory approvals and submissions, including interactions with the European Medicines Agency (EMA) for APL-130277, which is currently in Phase 3 clinical development in Europe.

              Lead Product(s): Apomorphine Hydrochloride

              Therapeutic Area: Neurology Product Name: Kynmobi

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Sunovion Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement September 02, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bial

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Portugal
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BIAL Takes the Lead in Europe for the Commercialisation of Epilepsy Treatment, Zebinix® Expanding Neurology Footprint

              Details:

              BIAL takes the lead for the marketing and distribution of Zebinix® (eslicarbazepine acetate) in Europe. Eslicarbazepine acetate is a once-daily anti-epileptic used to treat epilepsy patients with focal seizures (partial-onset seizures).

              Lead Product(s): Eslicarbazepine Acetate

              Therapeutic Area: Neurology Product Name: Zebinix

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eisai

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Termination February 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bial

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Portugal
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BIAL and Recipharm Expand Long-Term Supply Agreement for Opicapone API

              Details:

              The new agreement provides both companies with a long-term partnership that will ensure continued supply for patients across the globe. Opicapone (Ongentys) is approved in Europe, USA, South Korea, Taiwan, Australia and Japan.

              Lead Product(s): Opicapone

              Therapeutic Area: Neurology Product Name: Ongentys

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Recipharm AB

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY